SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec jumps on launching tetravalent vaccine ‘Easyfour-TT’

26 Dec 2016 Evaluate

Panacea Biotec is currently trading at Rs. 120.85, up by 5.95 points or 5.18% from its previous closing of Rs. 114.90 on the BSE.

The scrip opened at Rs. 114.80 and has touched a high and low of Rs. 127.00 and Rs. 110.10 respectively. So far 31,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 155.00 on 25-Jul-2016 and a 52 week low of Rs. 83.90 on 12-Feb-2016.

Last one week high and low of the scrip stood at Rs. 127.00 and Rs. 110.10 respectively. The current market cap of the company is Rs. 740.22 crore.

The promoters holding in the company stood at 74.60%, while Institutions and Non-Institutions held 0.13% and 25.27% respectively.

Panacea Biotec, one of India’s leading research based health management company, has launched Tetravalent Vaccine 'Easyfour-TT' for active primary immunization and booster dose against diphtheria, tetanus and pertussis (DTP) and Haemophilus Influenza Type B (Hib). Easyfour-TT (DTwP-Hib), world’s first fully liquid Tetravalent vaccine launch in India will protect infant from Diptheria, Tetanus, Whopping Cough, Hib-Meningitis.

Easyfour-TT is a sterile and uniform suspension, manufactured using CDAP technology with WHO Pre-Qualified antigens which ensures good quality, high immunogenicity and less reactogenicity. Being fully liquid, product requires no reconstitution, therefore saves time and minimizes chance of error. Easyfour-TT comes with a legacy of being a tried and tested brand in pediatric clinical trials ensuring good ethnic response with a better reactogenicity profile.

Panacea Biotec is the largest biotechnology company as well as among the top 50 pharmaceutical companies of India. The company has product portfolio that’s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.


Panacea Biotec Share Price

358.00 5.30 (1.50%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×